Multicentric Castleman Disease: A Rare Case of Generalised Lymphadenopathy in India

Jemima Islam *

Department of Internal Medicine, IPGMER & SSKM Hospital, Kolkata - 700020, India.

Md. Karimulla Mondal

Department of Internal Medicine, IPGMER & SSKM Hospital, Kolkata - 700020, India.

Vaibhav Agarwal

Department of Internal Medicine, IPGMER & SSKM Hospital, Kolkata - 700020, India.

Sumit Kumar Ghosh

Department of Internal Medicine, IPGMER & SSKM Hospital, Kolkata - 700020, India.

Soumitra Ghosh

Department of Internal Medicine, IPGMER & SSKM Hospital, Kolkata - 700020, India.

*Author to whom correspondence should be addressed.


Abstract

Castleman disease (CD) is a type of hematological disorder, classified based on the number of the regions of enlarged lymph node, histopathological features, and association with human herpes virus 8. It may be unicentric with single region of the lymph node enlarged, or multicentric with multiple regions of lymphadenopathy. Some cases of Multicentric Castleman Disease (MCD) are caused by human herpes virus 8 (75%) while in others it is HHV8 negative. The epidemiology of idiopathic MCD is poorly understood due to lack of diagnosis since it is a difficult clinical diagnosis and also require analysis from a pathologist that is not available worldwide. Diagnosis and treatment are incredibly challenging as it can presents with wide array of manifestation from asymptomatic to systemic manifestation. There is no exact treatment guideline, Anti IL6 monoclonal antibody with or without systemic steroid is the mainstay of treatment. Here, we report a case that was initially suspected to have a lymphoma but later histologically was confirmed to have Multicentric Castleman's Disease. Here we report a case of forty-year-old man with history of chronic fever & constitutional symptoms, anasarca, exertional dyspnea, easy fatiguability, palpitation and generalized lymphadenopathy on physical examination which later diagnosed as Multicentric Castleman Disease. He had bicytopenia, raised inflammatory markers, lymph node biopsy revealed Castleman disease like picture. All the possible differential diagnosis had been ruled out with respective investigations. He was treated with steroid and IL6 inhibitor Tocilizumab and the patient improved remarkably. 

Keywords: Castleman disease (CD), HHV8, unicentric, Multicentric Castleman Disease (MCD), Tocilizumab


How to Cite

Islam , J., Mondal , M. K., Agarwal , V., Ghosh , S. K., & Ghosh , S. (2023). Multicentric Castleman Disease: A Rare Case of Generalised Lymphadenopathy in India. International Journal of Research and Reports in Hematology, 6(2), 233–238. Retrieved from https://journalijr2h.com/index.php/IJR2H/article/view/128

Downloads

Download data is not yet available.

References

Iyer S, Bhatti MI, Halliday M. Castleman's disease-A case report. Int J Surg Case Rep. 2010;1(3):25-6.

DOI: 10.1016/j.ijscr.2010.06.005. Epub 2010 Oct 15. PMID: 22096669; PMCID: PMC3199674.

El-Osta HE, Kurzrock R. Castleman's disease: from basic mechanisms to molecular therapeutics. Oncologist. 2011; 16(4):497-511. DOI: 10.1634/theoncologist.2010-0212. Epub 2011 Mar 25.

PMID: 21441298; PMCID: PMC3228122.

Wojtyś M, Piekarska A, Kunc M, Ptaszyński K, Biernat W, Zaucha JM, Waloszczyk P, Lisowski P, Kubisa B, Grodzki T. Clinicopathological comparison and therapeutic approach to Castleman disease-a case-based review. J Thorac Dis. 2019 Nov;11(11):4859-4874. DOI: 10.21037/jtd.2019.10.73. PMID: 31903277; PMCID: PMC6940266.

Simpson D. Epidemiology of Castleman Disease. Hematol Oncol Clin North Am. 2018 Feb;32(1):1-10. DOI: 10.1016/j.hoc.2017.09.001. PMID: 29157611.

Mukherjee S, Martin R, Sande B, Paige JS, Fajgenbaum DC. Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6-directed therapy. Blood Adv. 2022 Jan 25;6(2):359-367.

DOI: 10.1182/bloodadvances.2021004441. PMID: 34535010; PMCID: PMC8791564.

Kojima, Masaru et al. “Idiopathic multicentric Castleman's disease. A clinicopathologic and immunohisto-chemical study of five cases.” Pathology, research, and practice. 2005;201(4):325-32. DOI: 10.1016/j.prp.2005.01.006

Tomohiro Koga, Remi Sumiyoshi, Atsushi Kawakami, Kazuyuki Yoshizaki, A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease, Modern Rheumatology. 2019; 29(2):302–305. Available:https://doi.org/10.1080/14397595.2018.1532383

Venkateswaran J, Balakrishna J. Castleman disease PathologyOutlines.com website https://www.pathologyoutlines.com/topic/lymphnodescastleman.html. Accessed March 30th, 2023.

Wang L, Chen H, Shi J, Tang H, Li H, Zheng W, Zhang F. Castleman disease mimicking systemic lupus erythematosus: A case report. Medicine (Baltimore). 2018 Sep;97(38):e12291.

DOI: 10.1097/MD.0000000000012291. PMID: 30235674; PMCID: PMC6160051.

van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018 Nov 15;132(20):2115-2124.

DOI: 10.1182/blood-2018-07-862334. Epub 2018 Sep 4. PMID: 30181172; PMCID: PMC6238190.